Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus

Journal of Infectious Diseases

Volumn 199, Issue 5, 2009, Pages 605-609

  Deresinski, Stan ^a,b,c  

^a STANFORD UNIVERSITY   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; DAPTOMYCIN; GENTAMICIN; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG TREATMENT FAILURE; ENDOCARDITIS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; UNITED STATES; VANCOMYCIN RESISTANCE;

EID: 61849106980     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/596630     Document Type: Note

References (48)

1. Ryffel C, Strässle A, Kayser FH, Berger-Bächi B. Mechanisms of heteroresistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1994; 38:724-8.
2. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-3.
3. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135- 6.
4. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sadar HS, Jones RN. Characterization of vancomycin heteroresistant Staphylococcus aureus (hVISA) from the Detroit Metropolitan area over a 22-year period (1986-2007). J Clin Microbiol 2008; 46:2950-4.
5. Lalani T, Federspiel JJ, Boucher HW, et al. Associations between the genotype of Staphylococcus aureus bloodstream isolates and the clinical characteristics and outcomes of bacteremic patients. J Clin Microbiol 2008; 46:2890-6.
6. Tenover C, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208-15.
7. Plipat N, Livni G, Bertram H, et al. Unstable vancomycin heteroresistance is common among clinical isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43:2494-6.
8. Yusof A, Engelhart A, Karlsson Å, et al. Evaluation of a new Etest vancomycin + teicoplanin strip for detection of glycopeptide intermediate Staphylococcus aureus (GISA) and heterogeneous GISA. J Clin Microbiol 2008; 46:3042-7.
9. Sieradzki K, Tomasz A. Alterations of cell wall structure and metabolism accompany reduced susceptibility in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 2003; 185:7103-10.
10. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47:3040-5.
11. Cui L, Iwamoto A, Lian JQ, Neoh HM, Maruyama T, Horikawa Y, Hiramatsu K. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:428-38.
12. Pereira PM, Filipe SR, Tomasz A, Pinho MG. Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3627-33.
13. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581-5.
14. Cuie L, Tominage E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:1079-82.
15. McAleese F, Wu SW, Sieradzki K, et al. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate-S. aureus-type resistance to vancomycin. J Bacteriol 2006; 188:1120-33.
16. Utaida S, Dunman PM, Macapagal D, et al. Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology 2003; 149:2719-32.
17. Mwangi MM, Wu SW, Sieradzki K, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 2007; 104:9451-6.
18. Howden BP, Stinear TP, Allen DL, Johnson PD, Ward PB, Davies JK. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to vancomycin-intermediate resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:3755-62.
19. Howden BP, Smith DJ, Mansell A, et al. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol 2008; 8:39.
20. Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother 2008; 52:45-53.
21. Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:1089-91.
22. Garzoni C, Francois P, Huyghe A, et al. A global view of Staphylococcus aureus whole genome expression upon internalization in human epithelial cells. BMC Genomics 2007; 8:171.
23. Tsuji BT, von Eiff C, Kelchlin PA, Kelchlin PA, Forrest A, Smith PF. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother 2008; 52:1533-7.
24. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51:1656-60.
25. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-402.
26. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492-502.
27. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50:3039-47.
28. Sakoulas G, Eliopoulos GM, Fowler VG Jr, et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005; 49:2687-92.
29. Boles BR, Horswill AR. Agr-mediated dispersal of Staphylococcus aureus biofilms. PLoS Pathog 2008; 4:e1000052.
30. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:2582-6.
31. Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 2006; 50:2330-6.
32. Sieradzki K, Tomasz A. Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus. Antimicrob Agents Chemother 2006; 50:527-33.
33. Nelson JL, Rice KC, Slater SR, et al. Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis. Antimicrob Agents Chemother 2007; 51:616-22.
34. Rice KC, Nelson JB, Patton TG, Yang SJ, Bayles KW. Acetic acid induces expression of the Staphylococcus aureus cidABC and lrgAB murein hydrolase regulator operons. J Bacteriol 2005; 187:813-21.
35. Barcia-Macay M, Lemaire S, Mingeot-Leclerq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of televancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58:1177-84.
36. Barcia-Macay M, Seral C, Mingeot-Leclerq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50:841-51.
37. Park WB, Lee JH, Jeon JH, et al. Effect of tumor necrosis factor-alpha on intracellular Staphylococcus aureus in vascular endothelial cells. FEMS Immunol Med Microbiol 2008; 52:247-52.
38. Khosrovaneh A, Riederer K, Saeed S, et al. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2004; 38:1328-30.
39. Kim MN, Hwang SH, Pyo YJ, Mun HM, Pai CH. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J Clin Microbiol 2002; 40:1376-80.
40. Bert F, Clarissou J, Durand F, et al. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J Clin Microbiol 2003; 41:5147-52.
41. Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353:1587-8.
42. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448-51.
43. Howden BP, Ward PB, Charles PGP, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-8.
44. Patel N, Graffunder E, Evans A, Helmecke M, Stellrecht K, Lodise TP. Relationship between hVISA and outcomes among patients with MRSA bloodstream infections treated with vancomycin (abstract P1461). In: Program and abstracts of the 18th European Congress of Clinical Microbiology and Infectious Diseases (Barcelona, Spain), 19-22 April 2008.
45. Daskalaki M, Rodriguez-Aranda A, Sanz F, Otero JR, Chaves F. Heteroresistant vancomycin-intermediate Staphylococcus aureus in associated to recurrent bacteraemia with the same strain (abstract P1463). In: Program and abstracts of the 8th European Congress of Clinical Microbiology and Infectious Diseases (Barcelona, Spain), 19-22 April 2008.
46. Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 2007; 45:1511-4.
47. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199:619-24 (in this issue).
48. Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, Cohen SN. SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 2004;305:1629-31.